TM-N1324

Research use only, not for human use.

TM-N1324 is a GPR39 agonist. TM-N1324 activates human GPR39 with high efficacy and potencies of 280 nM and 9 nM in the absence and presence of Zn2+, respectively.

TM-N1324 is a GPR39 agonist. TM-N1324 activates human GPR39 with high efficacy and potencies of 280 nM and 9 nM in the absence and presence of Zn2+, respectively. TM-N1324 has similar potencies to murine GPR39 with EC50s of 180 nM and 5 nM, respectively.(In Vitro):Measurements of somatostatin confirms that the GPR39 agonist TM-N1324 increases somatostatin release by 53%. TM-N1324 is found to have promising in vitro ADME properties. TM-N1324 has reasonably good aqueous solubility (65 μM at pH 7.0).

TM-N1324 activates human GPR39 with high efficacy and potencies of 280 nM and 9 nM in the absence and presence of Zn2+, respectively. TM-N1324 has similar potencies on murine GPR39, 180 nM and 5 nM. TM-N1324 is also found to have promising in vitro ADME properties.TM-N1324 has reasonably good aqueous solubility (65 μM at pH 7.0). Measurements of somatostatin confirms that the GPR39 agonist TM-N1324 increases somatostatin release by 53%.

——

——

Others

Other Targets

BTK

——

——

1144477-35-9

397.8

C18H13ClFN7O

>98% (HPLC)

In Vitro:?DMSO : 5 mg/mL (12.57 mM)

Cc1nn(c2N=C(O)CC(c12)c1ccc(F)cc1Cl)-c1ncnc2[nH]cnc12

——

(-20℃)

With Ice Pack

≥ 2 years